BASSO, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.764
AS - Asia 3.590
EU - Europa 1.565
SA - Sud America 679
AF - Africa 600
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 27
AN - Antartide 1
Totale 13.276
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.420
SG - Singapore 1.136
CN - Cina 634
VN - Vietnam 608
BR - Brasile 403
HK - Hong Kong 295
IT - Italia 295
DE - Germania 144
FI - Finlandia 140
FR - Francia 131
IN - India 95
BD - Bangladesh 76
IQ - Iraq 69
PL - Polonia 68
SE - Svezia 67
GB - Regno Unito 65
NL - Olanda 61
RU - Federazione Russa 55
AR - Argentina 50
TR - Turchia 49
CO - Colombia 41
JP - Giappone 39
CA - Canada 38
PH - Filippine 35
EC - Ecuador 33
PK - Pakistan 33
ID - Indonesia 32
BE - Belgio 31
VE - Venezuela 31
EG - Egitto 30
MX - Messico 30
SA - Arabia Saudita 30
UA - Ucraina 29
ZA - Sudafrica 29
AT - Austria 28
ES - Italia 27
JO - Giordania 27
KR - Corea 27
IE - Irlanda 26
MA - Marocco 26
PE - Perù 26
UZ - Uzbekistan 26
AZ - Azerbaigian 25
KG - Kirghizistan 25
PY - Paraguay 25
DO - Repubblica Dominicana 24
DZ - Algeria 24
JM - Giamaica 23
KE - Kenya 23
AM - Armenia 22
NP - Nepal 22
PR - Porto Rico 22
TN - Tunisia 22
HR - Croazia 21
KH - Cambogia 21
MY - Malesia 21
PS - Palestinian Territory 21
AO - Angola 20
BO - Bolivia 20
CL - Cile 20
EE - Estonia 20
RO - Romania 20
RS - Serbia 20
AL - Albania 19
BB - Barbados 19
CH - Svizzera 19
GA - Gabon 19
GR - Grecia 19
IL - Israele 19
MU - Mauritius 19
PT - Portogallo 19
BY - Bielorussia 18
DK - Danimarca 18
IR - Iran 18
LB - Libano 18
MN - Mongolia 18
UY - Uruguay 18
CI - Costa d'Avorio 17
MD - Moldavia 17
SO - Somalia 17
TW - Taiwan 17
AU - Australia 16
BG - Bulgaria 16
CM - Camerun 16
LU - Lussemburgo 16
LY - Libia 16
ML - Mali 16
PA - Panama 16
SI - Slovenia 16
SN - Senegal 16
YE - Yemen 16
CR - Costa Rica 15
ET - Etiopia 15
GP - Guadalupe 15
GT - Guatemala 15
LA - Repubblica Popolare Democratica del Laos 15
LV - Lettonia 15
MG - Madagascar 15
MK - Macedonia 15
MW - Malawi 15
Totale 12.619
Salva come PNG Salva come JPEG
Città #
Fairfield 900
Ashburn 742
Singapore 719
San Jose 625
Woodbridge 459
Houston 409
Chandler 391
Seattle 329
Cambridge 301
Wilmington 273
Hong Kong 267
Ann Arbor 230
Ho Chi Minh City 176
Beijing 146
Hanoi 137
Santa Clara 111
Boardman 109
Los Angeles 105
San Diego 89
Princeton 84
Jacksonville 74
Lauterbourg 64
Des Moines 59
Helsinki 59
Padova 56
Dong Ket 50
New York 49
Roxbury 49
Bytom 44
Munich 44
Medford 41
Chicago 39
São Paulo 36
Council Bluffs 34
Guangzhou 33
Baghdad 32
Da Nang 31
Nanjing 31
Tokyo 29
Buffalo 28
Milan 25
Falls Church 24
Amman 23
Baku 23
Tashkent 23
Turku 23
Hefei 22
Bishkek 21
Dublin 21
Haiphong 21
London 20
Vienna 20
Frankfurt am Main 19
Nairobi 19
Orem 19
Tallinn 19
Bridgetown 18
Libreville 18
Luanda 18
Nanchang 18
Phnom Penh 18
Rome 18
Ulan Bator 18
Yerevan 17
Bamako 16
Boston 16
Kingston 16
Montreal 16
Abidjan 15
Addis Ababa 15
Dakar 15
Lappeenranta 15
Lima 15
Nuremberg 15
San José 15
Panama City 14
Riga 14
Seoul 14
Tripoli 14
Antananarivo 13
Bogotá 13
Castries 13
Havana 13
Kuala Lumpur 13
Lahore 13
Managua 13
Nassau 13
Quito 13
Reykjavik 13
Stockholm 13
Warsaw 13
Amsterdam 12
Andorra la Vella 12
Ankara 12
Athens 12
Belgrade 12
Biên Hòa 12
Cairo 12
Chennai 12
Conakry 12
Totale 8.458
Salva come PNG Salva come JPEG
Nome #
Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection 363
Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1–HCV co-infected patients on effective combined anti-HIV treatment 300
Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014 295
Viral infections of the central nervous system in elderly patients: A retrospective study 294
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin 273
Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy. 266
Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: Complexity and vaccine implications 266
Epstein-Barr and cytomegalovirus DNA salivary shedding correlate with long-term plasma HIV RNA detection in HIV-infected men who have sex with men 260
Virological testing of cerebrospinal fluid in children aged less than 14 years with a suspected central nervous system infection: A retrospective study on 304 consecutive children from January 2012 to May 2015 259
Structural equation modelling of viral tropism reveals its impact on achieving viral suppression within 6 months in treatment-naive HIV-1-infected patients after combination antiretroviral therapy 249
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma 242
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver 238
Intra-hospital acquisition of colonization and infection by Klebsiella pneumoniae strains producing carbapenemases and carriage evolution: A longitudinal analysis in an Italian teaching hospital from January 2017 to August 2019 218
A case of persistent bacteraemia by Ralstonia mannitolilytica and Ralstonia pickettii in an intensive care unit 213
Viral molecular testing of cerebrospinal fluid in adults with suspected central nervous system infection in an italian university hospital laboratory: A retrospective study on 1462 consecutive patients 213
Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: A 24-month longitudinal study 209
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 203
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 201
HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection 195
Peripheral blood serum markers for apoptosis and liver fibrosis: are they trustworthy indicators of liver realness? 192
Structural-equation-modelling of the tropism impact on achieving viral suppression within six months in naïve HIV patients. 191
Long-term therapy with nevirapine and tropism 191
Detection of hepatitis C virus in an exhumed body identified the origin of a nosocomial transmission that caused multiple fatal diseases 191
Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy. 190
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. 187
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 187
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 186
Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004–2012 in the Veneto Region, Italy 183
Hbcab positivity is a risk factor for an increased detectability of hiv rna after switching to a two-drug regimen lamivudine-based (2dr-3tc-based) treatment: Analysis of a multicenter italian cohort 183
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 181
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 180
Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. 176
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 175
BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects 175
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 174
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors 173
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 167
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. 167
Prevalence, molecular epidemiology and intra-hospital acquisition of Klebsiella pneumoniae strains producing carbapenemases in an Italian teaching hospital from January 2015 to September 2016. 166
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 165
Time Course of Neutralizing Antibody in Health Care Workers with Mild or Asymptomatic COVID-19 Infection 163
Patterns of Transmitted Drug Resistance Mutations and HIV-1 Subtype Dynamics in ART-Naïve Individuals in Veneto, Italy, from 2017 to 2024 162
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. 160
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. 159
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. 158
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 158
Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients 157
Sustained virological response after treatment with direct-acting antivirals can help immune reconstitution in HIV-HCV coinfected patients even in case of persistent HIV low-level viremia 157
[Nailfold videocapillaroscopy in systemic sclerosis: diagnostic and follow-up parameters and correlation with both specific serum autoantibodies and subsets of skin involvement]. 156
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 156
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 154
Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. 153
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 153
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 150
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects 150
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. 149
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 149
Sustained Virological Response and Baseline Predictors in HIV-HCV Coinfected Patients Retreated with Pegylated Interferon and Ribavirin after Failing a Previous Interferon-Based Therapy: Systematic Review and Meta-Analysis 149
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant. 148
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. 145
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention 145
HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study 141
Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. 141
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study 137
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumor necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 134
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. 133
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals 132
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 127
HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch 120
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. 120
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 120
Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study 109
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients. 89
null 81
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis 26
Totale 13.378
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.715
article - articoli 37.715
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021181 0 0 0 0 0 0 0 0 0 0 99 82
2021/20221.054 22 142 103 42 40 41 60 82 131 21 183 187
2022/2023759 141 85 16 96 127 101 3 59 80 5 34 12
2023/2024349 17 40 43 33 21 25 31 26 8 25 34 46
2024/20251.595 5 63 39 60 229 66 88 142 117 74 301 411
2025/20266.511 346 565 922 1.182 592 268 852 570 721 363 130 0
Totale 13.378